Non-alcoholic Steatohepatitis Clinical Trials Market Size & Growth Forecast 2027–2036, By Segments (Phase, Study Design), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Non-alcoholic Steatohepatitis Clinical Trials Market size was estimated at USD 3.22 billion in 2026 and is projected to grow at a 6.68% CAGR from 2027 to 2036, attaining USD 6.15 billion by 2036. The industry revenue for 2027 is estimated at USD 3.4 billion.
Get more details on this report
Request Free Sample ReportNon-alcoholic Steatohepatitis Clinical Trials Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 51.83% of market share in 2026, supported by advanced clinical research infrastructure, strong liver disease research investment, established trial networks, and demand for innovative treatments.
- Asia Pacific is the fastest-growing region, driven by increasing obesity and metabolic disorders, improving healthcare infrastructure, expanding clinical research capabilities, and greater investment in specialized research centers.
Segment Momentum
- Phase III trials held a 55.93% market share in 2026, reflecting investment in advanced-stage therapy evaluation, broader patient studies, and extensive efficacy and safety assessments that require substantial clinical monitoring and data collection.
- Phase I is the fastest-growing segment as pharmaceutical and biotechnology developers advance novel therapies into early human evaluation, increasing demand for studies assessing initial safety, tolerability, pharmacokinetics, and dosing before larger clinical programs.
Market Expansion Drivers
- Rising prevalence of NASH and liver-related disorders.
- Advancements in clinical trial design & endpoints.
- Expansion of clinical trial sites in emerging regions.
Leading Market Participants
- Major players in the non-alcoholic steatohepatitis clinical trials market include IQVIA (USA), LabCorp Drug Development (USA), ICON (Ireland), Syneos Health (USA), PPD (USA), Medpace (USA), Charles River Laboratories (USA), Parexel (USA), Covance (USA), WuXi Clinical (China).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3.22 billion
- 2027 Estimated Market Size: USD 3.4 billion
- Projected Market Size: USD 6.15 billion by 2036
- Growth Forecast: 6.68% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Phase (Phase III) | Study Design (Interventional Studies)
- Emerging Opportunity Segment: Phase (Phase I) | Study Design (Interventional Studies)
Market Growth Drivers and Industry Trends
Rising prevalence of NASH and liver-related disorders
Growth of the non-alcoholic steatohepatitis clinical trials market is driven by the increasing prevalence of metabolic liver disorders associated with obesity, insulin resistance, type 2 diabetes, and other metabolic risk factors. The progressive nature of NASH, which can advance toward fibrosis, cirrhosis, and liver-related complications, is increasing the need for effective therapeutic interventions and disease-modifying approaches. As the clinical burden of liver disease expands, pharmaceutical and biotechnology research is increasingly focused on identifying therapies that can address steatohepatitis, fibrosis, and associated metabolic abnormalities, supporting sustained clinical trial activity.
Advancements in clinical trial design & endpoints
Advancements in clinical trial design and endpoint development are supporting growth by improving the ability to evaluate treatment efficacy and disease progression in NASH. Increasing use of non-invasive biomarkers, imaging-based assessments, histological evaluation, and composite endpoints is helping researchers characterize changes in liver fat, inflammation, and fibrosis while reducing reliance on invasive assessments. Greater standardization of patient selection and endpoint strategies is also facilitating more efficient trial development, enabling researchers to evaluate therapeutic candidates across different stages of disease and strengthening the overall clinical development pipeline.
Expansion of clinical trial sites in emerging regions
Expansion of clinical trial sites in emerging regions is increasing opportunities for NASH research by improving access to diverse patient populations and strengthening regional clinical research capabilities. Rising awareness of metabolic liver disease, development of healthcare infrastructure, and improvements in diagnostic capacity are enabling more patients to be identified and enrolled in clinical studies. Broader geographic distribution of trial sites can also support patient recruitment across different demographic and metabolic profiles, while the growing availability of specialized clinical research infrastructure is encouraging the inclusion of emerging markets in global NASH development programs.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of NASH and liver-related disorders | 2.5% | Short term (≤ 2 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Fast |
| Advancements in clinical trial design & endpoints | 2.5% | Medium term (2–5 yrs) | North America; Europe | High | Moderate |
| Expansion of clinical trial sites in emerging regions | 1.5% | Long term (5+ yrs) | Asia Pacific; Latin America | Low | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of 51.83% in 2026, driven by advanced clinical research infrastructure, strong investment in liver disease research, increasing prevalence of metabolic disorders, and growing demand for innovative treatments for non-alcoholic steatohepatitis. The region benefits from established clinical trial networks, sophisticated healthcare systems, and increasing adoption of advanced diagnostic and therapeutic approaches. Rising focus on disease progression, early intervention, and development of effective pharmacological treatments is encouraging pharmaceutical and research organizations to expand clinical studies, while growing awareness of the connection between metabolic health and liver disease is further supporting research activity.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region, supported by increasing prevalence of obesity and metabolic disorders, improving healthcare infrastructure, and expanding clinical research capabilities. Growing awareness of non-alcoholic steatohepatitis and its potential progression to advanced liver disease is encouraging greater diagnosis and research activity across the region. Increasing investments in healthcare and biotechnology, development of specialized research centers, and expanding access to clinical trial programs are creating favorable conditions for market growth. The region's large patient population and growing emphasis on developing treatments for chronic metabolic and liver conditions are further strengthening opportunities for clinical research.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Late-Stage Trial ActivityThe U.S. NASH clinical trials market is characterized by extensive development activity across pharmacological approaches, metabolic targets, and liver-directed therapies. Sponsors are prioritizing well-characterized patient populations, histological and non-invasive endpoints, efficient recruitment, and differentiated efficacy and safety profiles as programs progress through clinical development.
Germany 🇩🇪
Biomarker-Focused ResearchGermany’s NASH clinical trials market places strong emphasis on academically integrated research, advanced diagnostics, and rigorous patient characterization. Trial sponsors are increasingly focused on non-invasive biomarkers, imaging-based assessment, metabolic comorbidities, and well-defined clinical endpoints to improve patient selection and strengthen evidence generation.
Japan 🇯🇵
Metabolic Disease Trial FocusJapan’s NASH clinical trials market reflects strong interest in therapies addressing the interaction between liver disease and metabolic disorders. Development programs prioritize appropriate regional patient selection, non-invasive disease assessment, long-term safety monitoring, and clinical endpoints that can support regulatory evaluation and broader treatment adoption.
South Korea 🇰🇷
Translational Trial InfrastructureSouth Korea’s NASH clinical trials market is supported by advanced hospital infrastructure and growing interest in metabolic and liver disease therapeutics. Sponsors are prioritizing efficient patient identification, imaging and biomarker-based assessment, multicenter recruitment, and trial designs capable of generating robust evidence for novel mechanism-based treatments.
France 🇫🇷
Integrated Liver ResearchFrance’s NASH clinical trials market benefits from established hepatology research capabilities and access to specialized clinical centers. Current priorities include better phenotyping of patients, non-invasive fibrosis assessment, metabolic risk stratification, and trial designs that can evaluate meaningful liver outcomes while reducing dependence on invasive procedures.
Italy 🇮🇹
Specialist Patient RecruitmentItaly’s NASH clinical trials market is supported by specialist hepatology centers with experience in chronic liver disease research. Sponsors are focusing on targeted patient recruitment, standardized disease assessment, fibrosis monitoring, and investigator networks that can support complex protocols and improve consistency across multicenter studies.
Non-alcoholic Steatohepatitis Clinical Trials Market Share (%), by Phase, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportPhase Segment Analysis: Phase III (Largest Segment) vs Phase I (Fastest-Growing Segment)
In 2026, the phase III segment accounted for the largest market share of the non-alcoholic steatohepatitis clinical trials market at 55.93%, reflecting the substantial clinical development activity associated with advanced-stage evaluation of potential therapies. Phase III trials generally involve broader patient populations and are designed to generate extensive evidence regarding the efficacy and safety of investigational treatments, making them an important stage in the development pathway for non-alcoholic steatohepatitis therapies. The growing need for effective treatment options for a chronic liver condition associated with metabolic risk factors is supporting continued investment in late-stage clinical research. Advanced-stage studies also require comprehensive patient monitoring, clinical assessments, and data collection, contributing to demand for clinical trial services and related research capabilities.
The phase I segment is projected to experience the fastest growth, holding a rising share of the non-alcoholic steatohepatitis clinical trials market in 2026 as pharmaceutical and biotechnology developers increasingly advance novel therapeutic approaches into early-stage human evaluation. Phase I studies provide an essential foundation for assessing initial safety, tolerability, pharmacokinetic characteristics, and appropriate dosing considerations before therapies progress into larger clinical programs. The expanding research pipeline for non-alcoholic steatohepatitis includes approaches targeting different aspects of disease progression and metabolic dysfunction, creating opportunities for more investigational candidates to enter early clinical development. Greater emphasis on identifying viable therapies at an earlier stage is expected to support demand for phase I trials and associated clinical research services.
Study Design Segment Analysis: Interventional Studies (Largest & Fastest-Growing Segment)
The interventional studies segment represented the largest market share of the non-alcoholic steatohepatitis clinical trials market in 2026 and is also projected to be the fastest-growing study design segment. Interventional studies are central to therapeutic development because they allow researchers to evaluate the effects of investigational treatments under structured clinical conditions while monitoring safety and treatment response. Their importance is particularly pronounced in non-alcoholic steatohepatitis research, where clinical development requires careful assessment of disease progression, metabolic characteristics, liver-related outcomes, and treatment effects. The growing non-alcoholic steatohepatitis clinical trials pipeline of potential therapies is increasing the need for well-designed interventional trials capable of generating clinically relevant evidence. Advances in patient selection, clinical monitoring, biomarker assessment, and trial methodology are further supporting the effectiveness of these studies. As developers continue to investigate new treatment strategies and seek robust evidence for therapeutic efficacy and safety, interventional studies are expected to maintain a strong market share across the clinical trial landscape in 2026.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Phase | Phase I, Phase II, Phase III, Phase IV | Phase III | Phase I |
| Study Design | Interventional Studies, Observational Studies, Expanded Access Studies | Interventional Studies | Interventional Studies |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Advancing therapeutic pipelines in the non-alcoholic steatohepatitis (NASH) clinical trial landscape requires navigating complex trial designs and stringent regulatory hurdles. The integration of non-invasive biomarkers and advanced imaging offers a path to reduce patient burden from liver biopsies, though validation against histological benchmarks remains mandatory for regulatory acceptance. Simultaneously, trial sponsors face recruitment bottlenecks when enrolling advanced fibrosis cohorts, necessitating targeted patient identification strategies across global specialist centers. Pipeline progress increasingly relies on dual-mechanism combination therapies to address multifaceted liver disease, alongside aligning primary trial endpoints with established histological criteria to support accelerated regulatory approval pathways.
Major players in the non-alcoholic steatohepatitis clinical trials market:
- IQVIA (USA)
- LabCorp Drug Development (USA)
- ICON (Ireland)
- Syneos Health (USA)
- PPD (USA)
- Medpace (USA)
- Charles River Laboratories (USA)
- Parexel (USA)
- Covance (USA)
- WuXi Clinical (China)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| IQVIA (USA) | |||||||
| LabCorp Drug Development (USA) | |||||||
| ICON (Ireland) | |||||||
| Syneos Health (USA) | |||||||
| PPD (USA) | |||||||
| Medpace (USA) | |||||||
| Charles River Laboratories (USA) | |||||||
| Parexel (USA) | |||||||
| Covance (USA) | |||||||
| WuXi Clinical (China) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Boehringer Ingelheim | June 2024 | Boehringer Ingelheim released clinical trial results from a sub-analysis of its Survodutide Phase II study, demonstrating that up to 64.5% of adults with fibrosis stages F2 and F3 experienced liver fibrosis improvement without worsening of metabolic dysfunction-associated steatohepatitis. |
| Eli Lilly and Company | June 2024 | Eli Lilly and Company published detailed findings from the Phase 2 SYNERGY-NASH study evaluating tirzepatide across 190 patients with and without type 2 diabetes, advancing the clinical pipeline for metabolic dysfunction-associated steatohepatitis and stage 2 or 3 fibrosis. |
| Madrigal Pharmaceuticals | March 2024 | Madrigal Pharmaceuticals received FDA approval for Rezdiffra (resmetirom) to treat patients with noncirrhotic nonalcoholic steatohepatitis and moderate to advanced liver fibrosis, marking a major regulatory and commercial milestone for the therapeutic category. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Non-alcoholic Steatohepatitis Clinical Trials Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Trial Sponsor Type | Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutions, Government & Nonprofit Organizations |
| Therapeutic Approach | Pharmacological Therapies, Metabolic & Hormonal Therapies, Anti-inflammatory & Antifibrotic Therapies, Combination Therapies |
| Development Status | Recruiting, Active but Not Recruiting, Completed, Terminated or Withdrawn |
Non-alcoholic Steatohepatitis Clinical Trials Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Clinical Trial Recruitment & Patient Identification |
|
| Trial Design & Development Benchmarking |
|
| Clinical Development Risk & Regulatory Pathways |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the estimated worth of the non-alcoholic steatohepatitis clinical trials market?
What is the projected value of the non-alcoholic steatohepatitis clinical trials industry by 2036?
How are evolving NASH research priorities influencing clinical trial development strategies?
How are advances in clinical trial endpoints and emerging-region research capabilities shaping the NASH trials market?
Why does Phase III account for the largest share of the non-alcoholic steatohepatitis clinical trials market?
What is driving growth in Phase I non-alcoholic steatohepatitis clinical trials?
Why does North America lead the non-alcoholic steatohepatitis clinical trials market?
What is driving growth in Asia Pacific's non-alcoholic steatohepatitis clinical trials market?
Which companies dominate the non-alcoholic steatohepatitis clinical trials landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook